Monoclonal Antibody Therapy for Ebola Virus Disease.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

38 citing papers in PubMed, 70 citations in OpenAlex.

1. Computational mining of B cell receptor repertoires reveals antigen-specific and convergent responses to Ebola vaccination.Frontiers in immunology · 2024
   Trial
2. Molecular Insights into High-Pathogenicity RNA Viruses.Viruses · 2026
   Review
3. Identification and characterization of a broadly neutralizing and protective nanobody against the HA1 domain of H5 avian influenza virus hemagglutinin.Journal of virology · 2025
   Article
4. Generation of canine neutralizing antibodies against canine parvovirus by single B cell antibody technology.Archives of virology · 2024
   Article
5. Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control.Signal transduction and targeted therapy · 2024
   Review
6. Does monoclonal antibody treatment for COVID-19 impact short and long-term outcomes in a large generalisable population? A retrospective cohort study in the USA.BMJ open · 2023
   Article
7. Nanostructures for prevention, diagnosis, and treatment of viral respiratory infections: from influenza virus to SARS-CoV-2 variants.Journal of nanobiotechnology · 2023
   Review
8. Crystalline Antibody-Laden Alginate Particles: A Platform for Enabling High Concentration Subcutaneous Delivery of Antibodies.Advanced healthcare materials · 2023
   Article
9. Systematic analysis of human antibody response to ebolavirus glycoprotein shows high prevalence of neutralizing public clonotypes.Cell reports · 2023
   Article
10. Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants.Antiviral research · 2023
    Article
11. Ebanga™: The most recent FDA-approved drug for treating Ebola.Frontiers in pharmacology · 2023
    Review
12. Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies.Frontiers in microbiology · 2023
    Review
13. Risk factors for Ebola virus disease among household care providers, Sierra Leone, 2015.International journal of epidemiology · 2022
    Article
14. Monoclonal Antibodies for Pre- and Postexposure Prophylaxis of COVID-19: Review of the Literature.Pathogens (Basel, Switzerland) · 2022
    Review
15. Optimization of a mAb production process with regard to robustness and product quality using quality by design principles.Engineering in life sciences · 2022
    Article
16. An overview of the preclinical discovery and development of remdesivir for the treatment of coronavirus disease 2019 (COVID-19).Expert opinion on drug discovery · 2022
    Review
17. Antibody screening at reduced pH enables preferential selection of potently neutralizing antibodies targeting SARS-CoV-2.AIChE journal. American Institute of Chemical Engineers · 2021
    Article
18. Overview of Neutralizing Antibodies and Their Potential in COVID-19.Vaccines · 2021
    Review
19. Pan-ebolavirus protective therapy by two multifunctional human antibodies.Cell · 2021
    Article
20. Drug combination therapy for emerging viral diseases.Drug discovery today · 2021
    Review

Corrections and comments

• Comment on
  A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.2019

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as